Mixing new cocktails: Drug interactions in antiretroviral regimens

AIDS Patient Care and STDs

Volumn 19, Issue 5, 2005, Pages 286-297

  Young, Benjamin ^a  

^a ROSE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTACID AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ASTEMIZOLE; ATAZANAVIR; CARBAMAZEPINE; CYTOCHROME P450; DELAVIRDINE; DEXAMETHASONE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; HERBACEOUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; PHENOBARBITAL; PHENYTOIN; PRAVASTATIN; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RECREATIONAL DRUG; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STATINE DERIVATIVE; STAVUDINE; TENOFOVIR; TERFENADINE; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADDICTION; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DYSLIPIDEMIA; HEART ARRHYTHMIA; HERBAL MEDICINE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; METABOLIC DISORDER; MYOPATHY; OPPORTUNISTIC INFECTION; POLYPHARMACY; REVIEW; SELF MEDICATION; WITHDRAWAL SYNDROME; DRUG INTERACTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS;

EID: 20044364593     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.19.286     Document Type: Review

References (51)

1. Orrick JJ. Antiretroviral drug interactions. In: Steinhart C, Orrick JJ, Bentrup K, eds. HIV / AIDS Primary Care Guide. Tampa, Fl: Florida/Caribbean AIDS Education and Training Center; 2003:69-82.
2. Antoniou T, Gough K, Yoong D, Arbess G. Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. Clin Infect Dis 2004;38:e38-40.
3. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003;47: 130-137.
4. McNicholl IR. Drug interactions among the antiretrovirals. Curr Infect Dis Rep 2004;6:159-162.
5. Sheehan NL, Kelly DV, Tseng AL, et al. Evaluation of HIV drug interaction web sites. Ann Pharmacother 2003;37:1577-1586.
6. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. March 23, 2004:53. AIDSinfo.nih.gov. (Last accessed April 19, 2004).
7. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-996.
8. Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999;36:289-304.
9. Holder S. Important new pharmacokinetic data for Reyataz™ (atazanavir sulfate) in combination with Viread® (tenofovir disoproxil fumarate) [Letter to health care providers]. Bristol-Myers Squibb Company. August 8, 2003.
10. Viread (tenofovir disoproxil fumarate). In: Physicians' Desk Reference, 58th ed. Montvale, N.J.: Thomson, 2004:1397-1401.
11. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195-1211.
12. Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection. Med Letter Drugs Therapeut 2003; 45:90-92.
13. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J Clin Pharmacol 1998;38:106-111.
14. www.cmeonhiv.com/pub/interactions.among.hiv.protease.inhibitors.and.non. nucleoside.reverse.transcriptase.inhibitors. (Last accessed March 31, 2004).
15. Volberding PA. Initiating HIV therapy: timing is critical, controversial. Postgrad Med 2004;115:15-26.
16. Bertz R, Lam W, Hsu A, et al. Assessment of the pharmacokinetic interaction between ABT-378/ritonavir (ABT-378/r) and efavirenz (EFV) in healthy volunteers and in HIV+ subjects [Abstract 424]. In: Abstracts and Posters of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada: September 17-20, 2000.
17. Mouly S, Lown KS, Kernhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002;72:1-9.
18. Lupo L, Maa J-F, Dezii C, et al. Efficacy of efavirenz in different racial groups [Abstract P61]. In: Abstracts and Posters of the 6th International Congress on Drug Therapy in HIV Infection. Glasgow, UK: November 17-21, 2002.
19. Wegner S, Vahey M, Dolan M, et al. Racial differences in clinical efficacy of efavirenz-based antiretroviral therapy [Abstract 428-W]. In: Abstracts and Posters of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA: February 24-28, 2002.
20. Haas D, Ribaudo H, Kim R, et al. A common CYP2B6 variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG study NWCS214 [Abstract 133]. In: Abstracts and Posters of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: February 8-11, 2004.
21. van Heeswijk RP, Veldkamp A, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: A review of pharmacokinetics and clinical experience. Antivir Ther 2001;6: 201-229.
22. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9.
23. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60.
24. Agarwala S, Russo R, Mummaneni V, et al. Steady state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects [Abstract H-1716]. In: Posters and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA: September 27-30, 2002.
25. Boffito M, Moyle GJ. Pharmacokinetic considerations for combining 2 protease inhibitors. AIDS Read 2004;14:110-116.
26. MacManus S, Yates PJ, Elston RC, et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: Absence of protease resistance at 48 weeks. AIDS. 2004;18:651-655.
27. Mayers DL, Kohlbrenner VM, Dohnanyil C, et al. The inhibitory quotient (IQ) of tripranavir/ritonavir (TPV/r) in triple class experienced HIV+ patients: Results from BI 1182.52 [Abstract 9]. In: Program and Abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
28. Badaro R, DeJesus E, Lazzarin A, et al. efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (lpt/rtv) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16-week results from BMS AI424-045 [Abstract 18]. In: Program and Abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
29. McCallister S, Valdez H, Curry K, et al. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35:376-382.
30. Walmsley S, Leith, Katlama C, et al., Pharmacokinetics and safety of tipranavir/ritoanvir alone or in combination with saquinavir, amprenavir, or lopinavir: Interim analysis of BI1182.51 [Abstract WeOrB1236]. In: Abstracts and Posters of the XV International AIDS Conference. Bangkok, Thailand: July 12-16, 2004.
31. Hoggard PG, Kewn S, Barry MG, et al. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997;41:1231-1236.
32. Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000;182:321-325.
33. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:153-161.
34. Kearney BP, Plummer A, Sayre J, et al. Tenofovir DF (TDF) and didanosine EC (ddI EC): Investigation of pharmacokinetic (PK) drug-drug and drug-food interactions [Abstract LbPeB9026]. In: Abstracts and Posters of the XIV International AIDS Conference. Barcelona, Spain: July 7-12, 2002.
35. Kearney B, Flaherty J, Sayre J, et al. A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and lamivudine or didanosine [Abstract 337]. In: Abstracts and Posters of the International AIDS Society 2nd Conference on Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
36. Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004;48:1089-1095.
37. Young B, Baker R, Armon C, et al and the HIV Outpatient Study (HOPS) Investigators. Long-term assessment of the safety and tolerability of didanosine combined with tenofovir DF in ambulatory HIV-1 infected adult individuals [Abstract WePeB5922]. In: Abstracts and Posters of the XV International AIDS Conference. Bangkok, Thailand: July 12-16, 2004.
38. Grebely J, Raffa J, Gallagher L, et al. High virologic failure in patients receiving triple-NRTI therapy compared to standard HAART regimens containing tenofovir (TDF) in salvage therapy [Abstract 246P]. In: Abstracts and Posters of the 13th Annual Meeting of the Canadian Association for HIV Research. Montreal, Quebec: May 13-16, 2004.
39. Farthing C, Khaniou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients [Abstract 10607]. In: Abstracts and Posters of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
40. Gallant JE, Rodriguez AE, Weinberg W, et al. Early non-response of tenofovir in combination with abacavir and lamivudine in a randomized trial comparing this regimen to efavirenz in combination with abacavir and lamivudine [Abstract ESS30009, Unplanned Interim Analysis]. In: Abstracts and Posters of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: September 14-17, 2003.
41. Piliero P, Shachoy-Clark AD, Para M, et al. A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK protocol CNA 10905) [Abstract A-1797]. In: Abstracts and Posters of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: September 14-17, 2003.
42. Kearney BP, Isaacson E, Sayre J, et al. The pharmacokinetics of abacavir, a purine nucleoside analog, are not affected by tenofovir DF [Abstract A-1615]. In: Abstracts and Posters of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: September 14-17, 2003.
43. Ray A, Vela JE, Olson L, et al. Lack of negative interaction between tenofovir and abacavir in human cells [Abstract 2.3]. In: Abstracts and Posters of the 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy: April 1-3, 2004.
44. Hawkins T, Veikley W, St. Claire R, et al. Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside therapy [Abstract 2.4]. In: Abstracts and Posters of the 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy: April 1-3, 2004.
45. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-2315.
46. Boyd MA, Zhang X, Dorr A, et al. Lack of enzyme-inducing effect of rifampin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 2003;43:1382-1391.
47. Clotet B, Negredo E. HIV protease inhibitors and dyslipidemia. AIDS Rev 2003;5:19-24.
48. Kearney BP, Benhamou Y, Flaherty J, et al. Tenofovir pharmacokinetics in hepatic impairment and drug interaction potential with agents used to treat viral hepatitis [Abstract 600]. In: Abstracts and Posters of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: February 8-11, 2004.
49. Gries J-M, Torriani FJ, Rodriguez-Torres M, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV co-infection: Final results of a randomized clinical study [Abstract 136LB]. In: Abstracts and Posters of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: February 8-11, 2004.
50. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001;164:7-12.
51. Lesho EP, Gey DC. Managing issues related to antiretroviral therapy. Am Fam Physician 2003;68: 675-686.